Asian Pacific Journal of Cancer Prevention

  • 제15권20호
  • /
  • Pages.8591-8594
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Outcome of Daily Cisplatin with Thoracic Chemoradiotherapy in Advanced Non-small Cell Lung Cancer Patients with Comorbid Disorders: a Pilot Study

  • Kiziltan, Huriye Senay (Department of Radiation Oncology, Faculty of Health Sciences, Bezmialem Vakif University) ;
  • Bayir, Ayse Gunes (Department of Nutrition and Dietetics, Faculty of Health Sciences, Bezmialem Vakif University) ;
  • Tastekin, Didem (Department of Radiation Oncology, Faculty of Health Sciences, Bezmialem Vakif University) ;
  • Coban, Ganime (Department of Pathology, Faculty of Health Sciences, Bezmialem Vakif University) ;
  • Eris, Ali Hikmet (Department of Radiation Oncology, Faculty of Health Sciences, Bezmialem Vakif University) ;
  • Aydin, Teoman (Department of Physical Therapy and Rehabilitation, Faculty of Medicine, Bezmialem Vakif University) ;
  • Mayadagli, Alparslan (Department of Radiation Oncology, Faculty of Health Sciences, Bezmialem Vakif University)
  • 발행 : 2014.11.06
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Lung cancer is the most common cancer in males worldwide. The principal mode of treatment in the early stage of non-small cell lung cancer (NSCLC) is surgery. However, five-year survival is only about 15% for all stages. The aim is to investigate the effect of daily low dose cisplatin concurrently with radiation therapy in advanced NSCLC patients with poor performance status. Materials and Methods: Ten patients diagnosed as inoperable Stage IIIB NSCLC with comorbid disease were assessed retrospectively in Bezmialem Vakif University, Faculty of Medicine, Department of Radiation Oncology, between 2011 to 2013. ECOG performance status was between 3 and 4. Cisplatin was administered at $6mg/m^2$ daily, for 5 days a week concurrently with radiotherapy using 160-200 cGy daily fractions, 54 Gy being the lowest and 63 Gy being the highest dose. Results: Complete response at the primary tumour site was obtained in 20% patients. Grade I esophagitis was seen 70 percent of patients, and the grade II haematological toxicity rate was 20 %. Median survival time was 7 months. Conclusions: Median survival time was reasonable, despite the patients ECOG performance status of 3-4, which is similar to groups even without comorbid disorders in comparison to other published papers in the literature. Acceptable toxicity, high response rates and quality of life of patients are the other favourable features.

키워드

참고문헌

  1. Akerley W, Herndon JE, Egorin MJ, et al (2003). Weekly, highdose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the cancer and leukemia group B. Cancer, 97, 2480-6. https://doi.org/10.1002/cncr.11375
  2. Anonymous (1995). Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. non-small cell lung cancer collaborative group. BMJ, 311, 899-909. https://doi.org/10.1136/bmj.311.7010.899
  3. Biedermann B, Landmann C, Kann R, et al (2000). Combined chemoradiotherapy with daily low-dose cisplatin in locally advanced inoperable non-small cell lung cancer. Radiother Oncol, 56, 169-73. https://doi.org/10.1016/S0167-8140(00)00203-6
  4. Camps C, Massuti B, Jimenez A, et al (2006). Randomized phase IIIstudy of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish lung cancer group trial. Ann Oncol, 17, 467-72. https://doi.org/10.1093/annonc/mdj115
  5. Chang AY, Rubins J, Asbury R, et al (2001). Weekly paclitaxel in advanced non-small cell lung cancer. Semin Oncol, 28, 10-3.
  6. Chen CH, Chang J W, Lee CH, et al (2005). Dose-finding and phase 2 study of weekly paclitaxel (Taxol) and cisplatin combination in treating Chinese patients with advanced nonsmall cell lung cancer. Am J Clin Oncol, 28, 508-12. https://doi.org/10.1097/01.coc.0000182419.47882.51
  7. Cheng AM, Wood DE (2011). Surgical and endoscopic palliation of advanced lung cancer. Surg Oncol Clin N Am, 20, 779-90. https://doi.org/10.1016/j.soc.2011.07.008
  8. European organization for research and treatment of cancer (2000). Toxicity of high-dose radiotherapy combined with daily cisplatin in non-small cell lung cancer: results of the EORTC 08912 phase I/II study. Eur J Cancer, 36, 592-600. https://doi.org/10.1016/S0959-8049(99)00315-9
  9. Gauden S, Ramsay J, Tripeony L (1995). The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest, 108, 1278-82. https://doi.org/10.1378/chest.108.5.1278
  10. Goldstraw P, Crowley J, Chansky K, et al (2007). International association for the study of lung cancer international staging committee: participating institutions. J Thorac Oncol, 2, 706-14. https://doi.org/10.1097/JTO.0b013e31812f3c1a
  11. Greco FA (1999). Docetaxel (Taxotere) administrated in weekly schedules. Semin Oncol, 26, 28-31.
  12. Hainsworth JD, Burris HA 3rd, Erland JB, et al (1998). Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. Clin Oncol, 16, 2164-8.
  13. Jatoi A, Stella PJ, Hillman S, et al (2003). Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (${\geq}$65 years of age): a phase II north central cancer treatment group study. Am J Clin Oncol, 26, 441-7. https://doi.org/10.1097/01.coc.0000027460.53907.38
  14. Kaira K, Takise A, Minato K, et al (2005). Phase II study of weekly docetaxel and cisplatin in patients with non-small cell lung cancer. Anticancer Drugs, 16, 455-60. https://doi.org/10.1097/00001813-200504000-00013
  15. Luchtenborg M, Jakobsen E, Krasnik M, et al (2012). The effect of comorbidity on stage-specific survival in resected nonsmall cell lung cancer patients. Eur J Cancer, 48, 3386-95. https://doi.org/10.1016/j.ejca.2012.06.012
  16. Nieder C, Tollali T, Dalhaug A, et al (2014). Active anticancer treatment during the final month of life in patients with non-small cell lung cancer. Anticancer Res, 34, 1015-20.
  17. Pujol JL, Paz-Ares L, de Marinis F, et al (2014). Longterm and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer, 15, 418-25. https://doi.org/10.1016/j.cllc.2014.06.007
  18. Lester JF, Agulnik J, Akerborg O, et al (2013). What constitutes best supportive care in the treatment of advanced non-small cell lung cancer patients? results from the lung cancer economics and outcomes research (LUCEOR) study. Lung Cancer, 82, 128-35. https://doi.org/10.1016/j.lungcan.2013.06.023
  19. Li CH, Liu MY, Liu W, Li DD et al (2014). Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer. Asian Pac J Cancer Prev, 15, 731-6. https://doi.org/10.7314/APJCP.2014.15.2.731
  20. Natukula K, Jamil K, Pingali UR, et al (2013). Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide. Asian Pac J Cancer Prev, 14, 4661-6. https://doi.org/10.7314/APJCP.2013.14.8.4661
  21. Non-small cell lung cancer collaborative group (1995). Chemotherapy in non-small cell lung cancer: A metaanalysis using updated data on individual patients from 52 randomised controlled trial. BMJ, 311, 899-909. https://doi.org/10.1136/bmj.311.7010.899
  22. Noronha V, Patil VM, Joshi A, Prabhash K (2013). Efficacy and safety of metronomic administration of paclitaxel for advanced recurrent non-small-cell lung cancer. Indian J Cancer, 50, 122-7. https://doi.org/10.4103/0019-509X.117032
  23. Ramalingam SS, Dahlberg SE, Langer CJ, et al (2008). Outcomes for elderly, advanced-stage non-small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of eastern cooperative oncology group trial 4599. Clin Oncol, 26, 60-5. https://doi.org/10.1200/JCO.2007.13.1144
  24. Schaake-Koning C, van den Bogaert W, Dalesio O, et al (1992). Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med, 326, 524-30. https://doi.org/10.1056/NEJM199202203260805
  25. Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
  26. Simon TG, Beland MD, Machan JT, Dipetrillo T, Dupuy DE (2012). Charlson comorbidity index predicts patient outcome, in cases of inoperable non-small cell lung cancer treated with radiofrequency ablation. Eur J Radiol, 81, 4167-72. https://doi.org/10.1016/j.ejrad.2012.06.007
  27. Spiro SG, Rudd RM, Souhami RL, et al (2004). Chemotherapy versus supportive care in advanced non-small cell lung cancer: Improved survival without detriment to quality of life. Thorax, 59, 828-36. https://doi.org/10.1136/thx.2003.020164
  28. Tsunoda T, Koizumi T, Hayasaka M, et al (2004). Phase II study of weekly docetaxel combined with cisplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol, 54, 173-7.
  29. Zhou JN, Huang XE, Ye Z, Li C, et al (2009). Weekly paclitaxel/docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.

피인용 문헌

  1. Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4147